2B70.DE vs. LHTC.DE
2B70.DE (iShares Nasdaq US Biotechnology UCITS ETF) and LHTC.DE (Lyxor STOXX Europe 600 Healthcare UCITS ETF Acc) are both Health & Biotech Equities funds - 2B70.DE tracks the Nasdaq Biotechnology while LHTC.DE tracks the STOXX® Europe 600 Health Care. Both are passively managed. Over the past 5 years, 2B70.DE returned 5.68%/yr vs 5.04%/yr for LHTC.DE. A 0.57 correlation means they provide meaningful diversification when combined. 2B70.DE charges 0.35%/yr vs 0.30%/yr for LHTC.DE.
Performance
2B70.DE vs. LHTC.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, 2B70.DE achieves a 4.53% return, which is significantly higher than LHTC.DE's -2.55% return.
2B70.DE
- 1D
- 3.29%
- 1M
- 1.98%
- YTD
- 4.53%
- 6M
- 3.42%
- 1Y
- 39.14%
- 3Y*
- 10.00%
- 5Y*
- 5.68%
- 10Y*
- —
LHTC.DE
- 1D
- 3.03%
- 1M
- 1.33%
- YTD
- -2.55%
- 6M
- -0.81%
- 1Y
- 5.03%
- 3Y*
- 2.35%
- 5Y*
- 5.04%
- 10Y*
- 5.88%
2B70.DE vs. LHTC.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | 4.53% | 18.62% | 4.60% | 2.56% | -6.29% | 7.59% | 14.52% | 30.18% | -7.35% | 2.65% |
LHTC.DE Lyxor STOXX Europe 600 Healthcare UCITS ETF Acc | -2.55% | 7.11% | 3.92% | 7.59% | -6.20% | 25.48% | -1.95% | 27.54% | 2.95% | -0.71% |
Correlation
The correlation between 2B70.DE and LHTC.DE is 0.58, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.58 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.53 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.55 |
Correlation (All Time) Calculated using the full available price history since Nov 24, 2017 | 0.57 |
The correlation between 2B70.DE and LHTC.DE has been stable across timeframes, ranging from 0.53 to 0.58 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
2B70.DE vs. LHTC.DE — Risk / Return Rank
2B70.DE
LHTC.DE
2B70.DE vs. LHTC.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF (2B70.DE) and Lyxor STOXX Europe 600 Healthcare UCITS ETF Acc (LHTC.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| 2B70.DE | LHTC.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.74 | ||
| Sortino ratioReturn per unit of downside risk | +2.33 | ||
| Omega ratioGain probability vs. loss probability | 1.34 | 1.07 | +0.27 |
| Calmar ratioReturn relative to maximum drawdown | 6.15 | 0.40 | +5.75 |
| Martin ratioReturn relative to average drawdown | 17.06 | 0.89 | +16.17 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| 2B70.DE | LHTC.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.04 | 0.30 | +1.74 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.28 | 0.32 | -0.05 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.38 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.36 | 0.44 | -0.08 |
Drawdowns
2B70.DE vs. LHTC.DE - Drawdown Comparison
The maximum 2B70.DE drawdown since its inception was -30.87%, smaller than the maximum LHTC.DE drawdown of -40.53%. Use the drawdown chart below to compare losses from any high point for 2B70.DE and LHTC.DE.
Loading charts...
Drawdown Indicators
| 2B70.DE | LHTC.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -30.87% | -40.53% | +9.66% |
Max Drawdown (1Y)Largest decline over 1 year | -6.33% | -12.43% | +6.10% |
Max Drawdown (3Y)Largest decline over 3 years | -29.34% | -26.48% | -2.86% |
Max Drawdown (5Y)Largest decline over 5 years | -30.87% | -26.48% | -4.39% |
Max Drawdown (10Y)Largest decline over 10 years | — | -26.48% | — |
Current DrawdownCurrent decline from peak | -1.26% | -11.60% | +10.34% |
Average DrawdownAverage peak-to-trough decline | -10.01% | -9.31% | -0.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.29% | 5.67% | -3.38% |
Volatility
2B70.DE vs. LHTC.DE - Volatility Comparison
iShares Nasdaq US Biotechnology UCITS ETF (2B70.DE) has a higher volatility of 6.65% compared to Lyxor STOXX Europe 600 Healthcare UCITS ETF Acc (LHTC.DE) at 5.69%. This indicates that 2B70.DE's price experiences larger fluctuations and is considered to be riskier than LHTC.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| 2B70.DE | LHTC.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.65% | 5.69% | +0.96% |
Volatility (6M)Calculated over the trailing 6-month period | 14.26% | 11.67% | +2.59% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.09% | 16.60% | +2.49% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.34% | 15.44% | +4.90% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 21.76% | 15.57% | +6.19% |
2B70.DE vs. LHTC.DE - Expense Ratio Comparison
2B70.DE has a 0.35% expense ratio, which is higher than LHTC.DE's 0.30% expense ratio.
Dividends
2B70.DE vs. LHTC.DE - Dividend Comparison
Neither 2B70.DE nor LHTC.DE has paid dividends to shareholders.
Frequently Asked Questions
2B70.DE and LHTC.DE have a correlation of 0.58, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, LHTC.DE is cheaper at 0.30% per year. The better choice depends on whether you care most about return, fees, risk, or income.
LHTC.DE is cheaper with a 0.30% expense ratio, compared with 0.35% for 2B70.DE.
2B70.DE tracks Nasdaq Biotechnology, while LHTC.DE tracks STOXX® Europe 600 Health Care. They also come from different issuers: iShares and Amundi. Their fees differ too: 0.35% for 2B70.DE and 0.30% for LHTC.DE.
Find the right allocation for 2B70.DE and LHTC.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer